CMND — Clearmind Medicine Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1892500 ·
Last close
$3.45
Market Cap
$5.13M
52W High
$1273.60
52W Low
$3.24
ADV30
13,205
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jul 2026 0 — -2,179,875 -907,291 16,911,786 12,035,210 3,960,882
Apr 2026 0 — -1,571,209 -2,047,653 14,523,512 11,415,719 3,032,771
Jan 2026 0 — -3,659,915 -3,854,583 11,143,419 9,257,766 2,905,011
Oct 2025 0 — -1,456,258 -687,842 6,083,052 3,923,058 4,890,456

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,069,326
Investing CF
$-1,952,592
Financing CF
$17,569,464
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-137.28
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-34,689,251
Inventory
—
Receivables
$594,032
ST Investments
$3,894,226
EBIT TTM
$-7,477,266
Pretax Income TTM
$-7,484,674
Interest Exp TTM
$7,408
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Oct 2025 0 -5,667,177 -3,856,983 6,083,052 4,890,456 1,192,596 -4,734,498
Oct 2024 0 -5,744,925 -5,254,678 7,255,414 4,147,862 3,107,552 -4,858,659
Oct 2023 0 -6,303,434 -8,620,837 5,953,288 4,969,816 983,472 -6,301,472
Oct 2022 0 -6,251,431 -6,894,868 826,415 1,932,413 -1,105,998 -3,724,494

Peers — same industry

TickerNameMarket CapLastDaily %
PULM Pulmatrix, Inc. $5.00M $1.37 —
CDT CDT Equity Inc. $4.93M $0.36 —
PCSA Processa Pharmaceuticals, Inc. $4.84M $1.73 —
BLRX BioLineRx Ltd. $5.43M $1.12 —
ALZN Alzamend Neuro, Inc. $5.45M $1.13 —

News headlines (Yahoo Finance, 1h cache)

Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone
2026-11-16 12:37 · Yahoo
Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit
2026-11-10 12:32 · Yahoo
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
2026-10-27 12:22 · Yahoo
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
2026-10-12 11:55 · Yahoo
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
2026-10-08 11:32 · Yahoo
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
2026-10-07 12:40 · Yahoo
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations
2026-09-23 13:05 · Yahoo
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
2026-09-23 12:35 · Yahoo
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
2026-09-23 11:57 · Yahoo
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
2026-09-17 11:42 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.